EAST BRUNSWICK, N.J. and IRVINE, Calif., Oct. 18, 2011 /PRNewswire/ -- Amerigen Pharmaceuticals Limited and Stason Pharmaceuticals Inc. today announced they had entered into a collaboration agreement regarding the development of generic oral oncology products. Under the terms of the agreement, Stason will use its specialized containment facilities and formulation expertise to develop and manufacture products for Amerigen to commercialize in the United States and other territories. Stason received an up-front fee and is eligible for additional product-specific development milestones, plus manufacturing revenues and royalties on any commercialized products.
"This deal allows Amerigen to broaden the range of specialty oral products within its development portfolio," said Jonathan Embleton, Chief Business Officer for Amerigen. "We look forward to working with Stason to bring generic versions of some important critical care products to market and we are especially pleased to announce the concurrent filing of the first ANDA from this collaboration."
"We have been working hard to leverage our high containment development and manufacturing capabilities," said Jim Fang, Chief Operating Officer for Stason. "This opportunity allows Stason to fully develop and commercialize our pipeline of generic oral oncology products. We look forward to working with Amerigen to accomplish this goal."
Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in East Brunswick, NJ, USA. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Limited, is located in Suzhou, Jiangsu Province. The group has an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA and the Chinese SFDA. Amerigen's focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All of Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.
Stason Pharmaceuticals Inc. is a California-based pharmaceutical company involved in the development and manufacture of oral pharmaceuticals products. Stason develops products for itself as well as providing contract development and manufacturing services to the industry. Stason operates out of an FDA inspected 16,000 sq. ft. manufacturing facility capable of handling SafeBridge Catetgory I-IV, high containment and high potency compounds.
SOURCE Amerigen Pharmaceuticals Limited